DTC
MDGL icon

Deep Track Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Deep Track Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-905,000
Closed -$64.8M – 68
2022
Q2 		$64.8M Buy
905,000
+119,000
+15% +$8.75M 4.26% 7
2022
Q1 		$77.1M Buy
786,000
+286,000
+57% +$24.1M 4.95% 7
2021
Q4 		$42.4M Buy
+500,000
New +$41.1M 2.99% 10

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital's MDGL Position: Q3 2022 in Review

Deep Track Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2022, closing a stake of 905,000 shares — an estimated $64.8M sold.

Deep Track Capital first reported a position in MDGL in Q4 2021 and held it in 3 quarters. The position peaked at $77.1M in Q1 2022. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

  • Deep Track Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Deep Track Capital sold 905,000 Madrigal Pharmaceuticals shares in Q3 2022, an estimated $64.8M.
  • Deep Track Capital first reported a position in Madrigal Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Deep Track Capital's Madrigal Pharmaceuticals position peaked at $77.1M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on Deep Track Capital's 13F filing for Q3 2022, filed 14 Nov 2022.